Skip to main content
Fig. 2 | BMC Cancer

Fig. 2

From: Mucinous, endometrioid, and serous ovarian cancers with peritoneal dissemination are potent candidates for P-cadherin targeted therapy: a retrospective cohort study

Fig. 2

Cumulative disease-free survival and overall survival of ovarian cancer patients according to P-cadherin expression. Patients with a P-cadherin score of 0 to 3 were classified as showing Low expression, and patients with a score of 4 or more were classified as showing High expression. Kaplan-Meier curves showed a trend toward unfavorable survival in the High expression group in DFS (a, P = 0.0593) and OS (b, P = 0.0503)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us